

Table 1.22
U.S. Prevalence Counts, Invasive Cancers Only, January 1, 2011^a
Using Different Tumor Inclusion Criteria^b

Site	Sex	5-Year Limited Duration			36-year Limited Duration	
		1st Invasive Tumor Ever ^c	1st Per Site in Previous 36 Years ^d	1st Per Site in Previous 5 Years ^e	1st Invasive Tumor Ever ^c	1st Per Site in Previous 36 Years ^d
All Sites	Both Sexes	4,594,732	4,684,591	5,152,908	12,998,655	13,213,910
	Male	2,373,342	2,409,199	2,638,979	6,188,275	6,261,129
	Female	2,221,390	2,275,392	2,513,929	6,810,380	6,952,781
Oral Cavity & Pharynx	Both Sexes	104,979	121,403	125,889	272,072	300,609
	Male	73,503	84,311	87,116	181,087	198,337
	Female	31,476	37,092	38,773	90,985	102,272
Esophagus	Both Sexes	21,165	26,055	26,172	34,428	40,593
	Male	16,662	20,345	20,416	26,846	31,461
	Female	4,503	5,710	5,756	7,582	9,132
Stomach	Both Sexes	36,380	43,398	43,779	72,734	83,348
	Male	21,307	26,023	26,197	41,394	47,992
	Female	15,073	17,375	17,582	31,340	35,356
Colon & Rectum	Both Sexes	403,434	465,899	475,547	1,140,625	1,270,460
	Male	206,233	237,736	242,463	567,872	629,107
	Female	197,201	228,163	233,084	572,753	641,353
Liver & Intrahepatic Bile Duct	Both Sexes	33,682	38,427	38,461	45,468	50,961
	Male	24,703	27,797	27,819	32,312	35,854
	Female	8,979	10,630	10,642	13,156	15,107
Pancreas	Both Sexes	32,756	39,642	39,654	43,238	51,264
	Male	16,110	19,950	19,962	20,679	25,032
	Female	16,646	19,692	19,692	22,559	26,232
Larynx	Both Sexes	31,318	37,292	37,636	87,652	98,482
	Male	25,568	30,391	30,700	70,687	79,142
	Female	5,750	6,901	6,936	16,965	19,340
Lung & Bronchus	Both Sexes	231,126	297,286	306,343	395,186	487,438
	Male	107,276	140,106	143,631	179,129	222,121
	Female	123,850	157,180	162,712	216,057	265,317
Melanoma of the Skin	Both Sexes	282,028	320,618	335,149	924,397	998,829
	Male	151,313	176,523	185,633	459,686	503,903
	Female	130,715	144,095	149,516	464,711	494,926
Breast	Female	855,411	924,344	982,776	2,847,146	3,016,451
Cervix	Female	39,578	41,703	41,825	211,309	217,336
Corpus & Uterus, NOS	Female	177,109	198,883	199,045	584,180	637,931
Ovary ^f	Female	58,762	67,726	67,789	173,192	194,691

^a U.S. 2011 cancer prevalence counts are based on 2011 cancer prevalence proportions from the SEER 9 registries and 1/1/2011 U.S. population estimates based on the average of 2010 and 2011 population estimates from the U.S. Bureau of the Census.

^b Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion:

^c (c) First invasive tumor ever

^d (d) First invasive tumor for each cancer site diagnosed during the previous 36 years (1975-2010)

^e (e) First invasive tumor for each cancer site diagnosed during the previous 5 years (2006-2010)

For definitions (d) and (e) all sites is treated as a separate cancer "site".

Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 2006; Melanoma in 2007.

In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 36-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred more than 5 years prior to 1/1/2011.

In method (d) the 1981 melanoma is counted for the melanoma and all sites 36-year limited duration prevalence. The 2006 breast cancer is counted for the breast 5-year and 36-year limited duration prevalence.

In method (e) the 2006 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 2007 melanoma is counted for 5-year limited duration prevalence for melanoma.

^f Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

Table 1.22 - continued
 U.S. Prevalence Counts, Invasive Cancers Only, January 1, 2011^a
 Using Different Tumor Inclusion Criteria^b

Site	Sex	5-Year Limited Duration			36-year Limited Duration	
		1st Invasive Tumor Ever ^c	1st Per Site in Previous 36 Years ^d	1st Per Site in Previous 5 Years ^e	1st Invasive Tumor Ever ^c	1st Per Site in Previous 36 Years ^d
Prostate	Male	1,047,674	1,131,608	1,131,634	2,706,583	2,883,365
Testis	Male	42,114	42,942	43,546	212,079	214,995
Urinary Bladder	Both Sexes	200,849	251,314	256,779	560,445	653,826
	Male	152,753	192,335	196,676	418,562	489,001
	Female	48,096	58,979	60,103	141,883	164,825
Kidney & Renal Pelvis	Both Sexes	149,969	182,913	185,010	347,916	406,298
	Male	91,313	113,044	114,471	206,735	243,752
	Female	58,656	69,869	70,539	141,181	162,546
Brain & Nervous System	Both Sexes	44,217	47,403	47,827	131,408	135,930
	Male	24,099	25,776	26,028	69,809	72,101
	Female	20,118	21,627	21,799	61,599	63,829
Thyroid	Both Sexes	174,786	194,868	195,449	527,919	564,773
	Male	38,665	45,067	45,197	114,267	125,269
	Female	136,121	149,801	150,252	413,652	439,504
Hodgkin Lymphoma	Both Sexes	38,529	41,043	41,065	172,689	177,526
	Male	20,912	22,396	22,407	89,550	92,081
	Female	17,617	18,647	18,658	83,139	85,445
Non-Hodgkin Lymphoma	Both Sexes	203,992	239,804	242,418	522,113	584,133
	Male	109,031	129,460	130,668	274,206	307,672
	Female	94,961	110,344	111,750	247,907	276,461
Myeloma	Both Sexes	52,505	62,629	62,743	83,118	95,874
	Male	28,573	34,693	34,761	45,299	52,835
	Female	23,932	27,936	27,982	37,819	43,039
Leukemia	Both Sexes	115,823	134,637	135,040	297,129	327,520
	Male	66,545	78,337	78,566	168,443	186,907
	Female	49,278	56,300	56,474	128,686	140,613
Acute Lymphocytic Leukemia	Both Sexes	16,260	16,720	16,720	68,728	69,433
	Male	9,051	9,286	9,286	37,729	38,032
	Female	7,209	7,434	7,434	30,999	31,401
Childhood (Ages 0-19)	Both Sexes	63,918	63,993	64,508	314,920	315,399
	Male	33,711	33,746	33,991	162,108	162,335
	Female	30,207	30,247	30,517	152,812	153,064
Kaposi Sarcoma	Both Sexes	7,194	7,680	7,680	25,504	26,815
	Male	6,655	7,078	7,078	24,134	25,255
	Female	539	602	602	1,370	1,560
Mesothelioma	Both Sexes	3,004	3,922	3,922	4,663	5,734
	Male	2,172	2,854	2,854	2,829	3,595
	Female	832	1,068	1,068	1,834	2,139

^a U.S. 2011 cancer prevalence counts are based on 2011 cancer prevalence proportions from the SEER 9 registries and 1/1/2011 U.S. population estimates based on the average of 2010 and 2011 population estimates from the U.S. Bureau of the Census.

^b Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion:

^c (c) First invasive tumor ever

^d (d) First invasive tumor for each cancer site diagnosed during the previous 36 years (1975-2010)

^e (e) First invasive tumor for each cancer site diagnosed during the previous 5 years (2006-2010)

For definitions (d) and (e) all sites is treated as a separate cancer "site".

Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 2006; Melanoma in 2007.

In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 36-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred more than 5 years prior to 1/1/2011.

In method (d) the 1981 melanoma is counted for the melanoma and all sites 36-year limited duration prevalence. The 2006 breast cancer is counted for the breast 5-year and 36-year limited duration prevalence.

In method (e) the 2006 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 2007 melanoma is counted for 5-year limited duration prevalence for melanoma.

Table 1.23
U.S. Complete Prevalence Counts, Invasive Cancers Only, January 1, 2011^a
By Age at Prevalence

Site/Sex	Age at Prevalence								
	All Ages ^c	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70+
All Sites									
Males	6,271,036	19,001	41,846	85,407	155,919	356,211	883,826	1,658,545	3,070,283
Females	7,126,123	16,447	36,376	88,223	226,162	638,879	1,316,044	1,758,236	3,045,756
Oral Cavity & Pharynx									
Males	186,491	62	423	1,548	3,544	14,256	45,288	58,097	63,273
Females	95,100	90	522	1,483	3,689	8,554	18,160	23,692	38,911
Esophagus									
Males	26,909	0	0	22	144	1,109	4,697	9,747	11,190
Females	7,642	0	0	11	11	240	1,378	1,832	4,170
Stomach									
Males	42,127	0	29	62	603	2,502	7,119	11,218	20,593
Females	31,908	4	23	154	618	2,252	4,650	6,664	17,543
Colon & Rectum									
Males	575,457	11	69	1,276	5,758	25,233	82,732	139,236	321,141
Females	586,969	0	67	1,472	5,551	23,983	70,097	112,784	373,015
Liver & Intrahep									
Males	32,389	556	508	616	547	1,590	10,492	11,364	6,716
Females	13,553	396	521	359	403	889	3,016	3,463	4,506
Pancreas									
Males	20,801	23	12	130	276	1,653	4,466	6,626	7,615
Females	22,737	0	62	212	431	1,446	3,801	6,179	10,604
Larynx									
Males	71,999	0	0	90	219	1,822	10,381	21,280	38,207
Females	17,266	0	0	36	135	841	3,336	4,868	8,051
Lung & Bronchus									
Males	183,215	45	110	405	1,195	5,366	24,255	54,762	97,077
Females	219,111	23	71	367	1,387	7,548	29,898	59,021	120,797
Melanoma of the Skin									
Males	471,220	56	594	5,039	17,738	46,603	97,543	130,762	172,885
Females	489,011	68	878	10,864	34,091	73,459	115,119	113,905	140,628

^a U.S. 2011 cancer prevalence counts are based on 2011 cancer prevalence proportions from the SEER 9 registries (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta) and 1/1/2011 U.S. population estimates based on the average of 2010 and 2011 population estimates from the U.S. Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

^b Cases diagnosed more than 36 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

^c Due to rounding, the sum of the age specific estimates may not equal the all ages estimate.

Table 1.23 - continued
 U.S. Complete Prevalence Counts, Invasive Cancers Only, January 1, 2011^a
 By Age at Prevalence

Site/Sex	Age at Prevalence								
	All Ages ^c	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70+
Breast									
Males	14,871	0	0	22	112	591	1,838	4,277	8,030
Females	2,899,726	0	47	2,669	35,679	215,380	550,120	795,921	1,299,910
Cervix									
Females	249,632	0	57	2,142	15,934	41,969	59,700	57,440	72,389
Corpus & Uterus, NOS									
Females	610,804	12	12	581	5,712	25,316	89,564	165,807	323,801
Ovary ^d									
Females	188,867	45	1,063	3,475	6,807	18,458	41,719	49,281	68,021
Prostate									
Males	2,707,821	34	47	113	332	20,758	235,407	776,168	1,674,962
Urinary Bladder									
Males	425,722	57	88	567	2,476	10,749	43,060	102,624	266,102
Females	145,796	56	46	219	1,015	4,094	13,710	30,955	95,700
Kidney & Renal Pelvis									
Males	212,703	1,458	2,458	2,630	5,254	18,386	41,683	61,520	79,315
Females	145,900	1,374	2,649	2,922	4,870	12,287	25,458	35,857	60,483
Hodgkin Lymphoma									
Males	96,100	186	2,493	9,242	16,547	23,764	22,436	14,185	7,247
Females	89,693	67	2,083	9,407	16,399	23,306	19,845	11,219	7,368
Non-Hodgkin Lymphoma									
Males	278,836	842	3,598	7,821	13,627	29,722	54,887	71,106	97,233
Females	252,083	519	1,758	4,663	8,663	21,422	42,382	60,220	112,455
Myeloma									
Males	45,388	0	6	99	490	3,274	8,260	14,917	18,342
Females	37,979	0	0	28	312	2,325	6,791	11,124	17,399
Leukemia									
Males	170,969	6,686	13,047	12,524	11,179	14,206	23,300	35,001	55,027
Females	131,831	5,729	10,353	11,342	9,836	10,094	15,793	22,736	45,948
Acute Lymphocytic Leuk									
Males	39,514	5,599	11,159	9,649	6,330	3,974	1,505	836	463
Females	32,723	4,763	8,785	8,138	5,414	3,188	1,137	816	483

^a U.S. 2011 cancer prevalence counts are based on 2011 cancer prevalence proportions from the SEER 9 registries (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta) and 1/1/2011 U.S. population estimates based on the average of 2010 and 2011 population estimates from the U.S. Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

^b Cases diagnosed more than 36 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

^c Due to rounding, the sum of the age specific estimates may not equal the all ages estimate.